Rilpivirine
- Generic Name
- Rilpivirine
- Brand Names
- Complera, Edurant, Juluca, Odefsey, Rekambys
- Drug Type
- Small Molecule
- Chemical Formula
- C22H18N6
- CAS Number
- 500287-72-9
- Unique Ingredient Identifier
- FI96A8X663
- Background
Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potency and reduces the chance of resistance c...
- Indication
Rilpivirine, in combination with other agents, is indicated for the treatment of HIV-1 infections in antiretroviral treatment-naive patients with HIV-1 RNA ≤100,000 copies/mL and CD4+ cell count >200 cells/mm. The FDA combination therapy approval of rilpivirine and dolutegravir is indicated for adults and adolescents 12 years of age and older weighing at lea...
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1), Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed
- First Posted Date
- 2019-07-09
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 26
- Registration Number
- NCT04012931
- Locations
- 🇪🇸
Hosp. Univ. La Paz, Madrid, Spain
🇿🇦Josha Research, Bloemfontein, South Africa
🇹🇭Siriraj Hospital Mahidol University, Bangkok, Thailand
Effect on HIV Medications on EPC Cells
- Conditions
- Interventions
- First Posted Date
- 2018-12-20
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- Sabyasachi Sen
- Target Recruit Count
- 22
- Registration Number
- NCT03782142
- Locations
- 🇺🇸
The GW Medical Faculty Associates, Washington, District of Columbia, United States
Efficacy of Rilpivirine-based Regimens as Switch Therapy From Nevirapine-based Regimens in HIV-infected Patients
- Conditions
- Interventions
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Mahidol University
- Target Recruit Count
- 106
- Registration Number
- NCT03664440
- Locations
- 🇹🇭
Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
Darunavir and Rilpivirine Interactions With Levonorgestrel Implant
- Conditions
- Interventions
- First Posted Date
- 2018-07-17
- Last Posted Date
- 2019-03-28
- Lead Sponsor
- Makerere University
- Target Recruit Count
- 60
- Registration Number
- NCT03589027
- Locations
- 🇺🇬
Infectious Diseases Institue, Kampala, Uganda
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
- Conditions
- Interventions
- First Posted Date
- 2018-07-17
- Last Posted Date
- 2019-03-28
- Lead Sponsor
- Makerere University
- Target Recruit Count
- 60
- Registration Number
- NCT03589040
- Locations
- 🇺🇬
Infectious Diseases Institue, Kampala, Uganda
A Study to Investigate the Effect of Different Particle Sizes on the Single-dose Pharmacokinetics of Rilpivirine After Intramuscular Injection of a Long-acting Nanosuspension in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 110
- Registration Number
- NCT03127189
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
Rilpivirine in Virologically Suppressed Adolescents
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Mahidol University
- Target Recruit Count
- 100
- Registration Number
- NCT03033368
Interaction With HIV Antiretroviral Agents
- Conditions
- Interventions
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 40
- Registration Number
- NCT02556268
A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies
- Conditions
- Interventions
- First Posted Date
- 2015-07-13
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Sciences Ireland UC
- Target Recruit Count
- 48
- Registration Number
- NCT02494986
Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive
- First Posted Date
- 2015-06-12
- Last Posted Date
- 2016-06-30
- Lead Sponsor
- Juan A. Arnaiz
- Target Recruit Count
- 150
- Registration Number
- NCT02470650
- Locations
- 🇪🇸
Josep Mallolas Masferrer, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.